Soligenix Inc. is a biopharmaceutical company focused on developing innovative therapies for significant unmet medical needs. The company specializes in the research and clinical development of proprietary products aimed at treating rare diseases, as well as products intended for biodefense applications. With a strong emphasis on developing treatments for conditions such as oral mucositis and acute radiation syndrome, Soligenix takes a multi-faceted approach that includes leveraging its drug development platforms and engaging in collaborations with various stakeholders to advance its pipeline. The company’s dedication to improving patient outcomes drives its commitment to delivering safe and effective therapeutic options. Read More
About 3 million people in the U.S. live with irritable bowel disease (IBD), and its prevalence is rising. Unfortunately, there isn’t a cure for the condition at the moment. Many individuals with IBD develop clots in their blood and these can result in strokes and heart attacks . Now a new study has discovered possible reasons why these clots are common and suggests a possible way to address this problem while also reducing inflammation.
With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to tackle medical challenges where conventional treatments have failed to deliver meaningful solutions, recently reported on its progress so far this year ( https://ibn.fm/1dhGj ).
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Synergy CHC Corp. (NASDAQ: SNYR) is supercharging its retail expansion with a nationwide rollout of FOCUSfactor® Focus + Energy through EG America, the 6th largest U.S. convenience chain . The deal instantly places the functional brain health beverage in 1,600+ high-traffic locations , including Cumberland Farms, Turkey Hill, Tom Thumb (Albertsons Companies Inc. – NYSE: ACI), Loaf ’N Jug, and Minit Mart .
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the U.S. FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for treatment of Behçet’s Disease. The designation follows a review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients.
With global security threats driving demand for advanced biodefense solutions, Soligenix (NASDAQ: SNGX) is advancing RiVax(R), a heat-stable recombinant vaccine candidate aimed at protecting against deadly ricin toxin exposure. Supported by proprietary stabilization technology and robust preclinical data demonstrating long-lasting immunity, SNGX’s RiVax represents both a critical public safety innovation and a significant market opportunity in the specialized vaccine sector.
